Virus load and liver damage, as measured by quantitative polymerase chain reaction and histology activity index, were related to genotype and core promoter mutations in 43 chronic hepatitis B virus (HBV) carriers of East Asian origin. T-1762 mutants were more frequent in genotype C strains and were associated with more inflammation ( ) and fibrosis P ϭ .0036 ( ) of the liver but not with hepatitis B e antigen (HBeAg) status or virus load. P ϭ .0088 Conversely, precore mutations were associated with less liver inflammation ( ), which P ϭ .08 was linked to HBeAg negativity and lower viral replication. Carriers with genotype C were more often HBeAg positive ( ) with precore wild type strains and more-severe liver P ϭ .03 inflammation ( ) than were those with genotype B. These findings suggest that path-P ϭ .009 ogenic differences between genotypes may exist and that the T-1762 mutation may be useful as a marker for progressive liver damage but seem to contradict that down-regulation of HBeAg production is the major effect of this mutation.
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Chronic hepatitis B is a major health problem and may lead to cirrhosis and hepatocellular carcinoma. The liver damage in hepatitis B virus (HBV) infection is thought to result from the immune response and not from a cytopathic effect of the virus itself. Thus, the course of infection depends on several factors that influence the immune response, such as age at infection, genetic host factors (including HLA type), and probably the genetic variability of the virus, which influences the expression of viral antigens.
The genetic variability of HBV is observed both as the evolution of genotypes, that is, a divergence of the viral genome in the carrier population, and as the emergence of mutations in each infected subject. Several studies have investigated the effect of mutations on the clinical course of chronic hepatitis B. Mutations at nt 1762-1764 in the core promoter region have been associated with more-severe liver damage [1, 2] and with increased response to interferon [3] . However, the biologic effects of these mutations are not fully clarified. They have previously been linked to a "hepatitis B e antigen (HBeAg)-negative phenotype" [4] but have also been observed in the HBeAg-positive stage, in agreement with the experimental observation that they cause a relatively moderate down-regulation of the synthesis of HBeAg [5] [6] [7] . Some [5, 6, 8] but not all [7] studies have reported higher viral replication in strains with mutations at nt 1762-1764, possibly of importance for the induction of fulminant hepatitis [9] or the course of chronic HBV infection.
Six HBV genotypes (A-F) have been described [10, 11] . Genotypes B and C prevail in East Asia, where more than half of the estimated 300 million carriers in the world live. Unlike hepatitis C virus (HCV), genotype-related differences in the pathogenicity of HBV have not yet been described. However, in a large-scale Japanese study, more severe liver disease was found in carriers infected with HBV of serotype adr (i.e., genotype C) than in carriers with adw (mainly genotype B in Japan); moreover, this was associated with a difference in HBeAg status [12] .
To investigate these associations further, we analyzed the liver damage in East Asian HBV carriers infected with genotypes B and C in relation to viral replication and mutations in the core promoter and precore regions.
Methods
Patients. Serum samples from 48 chronic HBV carriers of East Asian origin were analyzed, and the liver damage in patients carrying HBV genotypes B ( ) or C ( ) was compared. n ϭ 23 n ϭ 20 These 43 subjects were from the following countries: Vietnam, 25; Thailand, 6; Korea, 6; China, 2; and 1 each from Indonesia, the Philippines, Malaysia, and Laos. All lacked antibodies to HCV and hepatitis delta virus.
Genotyping. Genotyping by restriction fragment length polymorphism of an S region [13] or a pre-S region amplicon [14] identified genotypes A, B, or C in 45 serum samples. In 2 cases, the genotype was established after sequencing (see below) by analysis of a few key nucleotides in the X region, which we have found to be strongly linked to genotypes; nt 1726-1727/1730 (CT/G specific for genotype B) and nt 1802 (T specific for genotypes B and C). Sequencing. After polymerase chain reaction (PCR) using the outer primers 1603F (5 -GTTGCATGGAGACCACCGTGAAC) and 2058R (5 -GTATGGTGAGGTGAACAATG) or 2160R (5 -CTGACTACTAATTCCCTGGATGCTGGGTCT) and the inner primers 1603F or 1680F (5 -ATGTCGACAACCGACCTTGA) and 2058R, sequencing was done by the chain-termination method. Each amplicon was analyzed in both sense and antisense directions with 1680F or 1603F and 2058R, respectively, as primers in a cyclesequencing reaction by use of fluorescent dye terminators. The sequence was read in an automated capillary sequence reader (Prism 310; Applied Biosystems, Foster City, CA) and analyzed by computer (Sequence Navigator software; Applied Biosystems).
Mutation analysis. The variability at nt positions 1858 and 1896 was analyzed with amplification-created restriction site methods as previously described [15] and by sequencing as described above. Mutations in the core promoter were analyzed by sequencing.
Serology. HBeAg and anti-HBe were analyzed by HBeAg IMX (Abbott Laboratories, Abbott Park, IL). HCV antibodies were analyzed by an anti-HCV system (Murex Diagnostics, Dartford, UK). Delta antibodies were analyzed by RIA (Abbott).
Quantitative PCR. Serum samples taken at the time of liver biopsy were analyzed by Amplicor HBV monitor (Roche Diag- nostic Systems, Sommerville, NJ) according to the manufacturer's instructions. The detection range for this test is 10 3 to 10 7 copies/mL [16] . To extend the detection range, samples with HBV DNA above 10 7 copies/mL were reanalyzed after predilution 1:10 4 in negative serum.
Histopathology activity index (HAI) and alanine aminotransferase (ALT). HAI was scored as described by Knodell et al. [17] in a blinded fashion. HAIinfl, that is, the sum of the component scores for piecemeal necrosis, lobular inflammation, and portal inflammation, and HAIfibr, the fibrosis score, were analyzed separately. ALT levels at the time of liver biopsy were recorded.
Statistics. HAI scores were compared by Mann-Whitney rank sum test and Fisher's exact test and ALT values by Mann-Whitney rank sum test. ). In P ϭ .036 agreement, HBV DNA levels were higher in subjects with genotype C, but not significantly: For genotypes B and C, respectively, the median HBV DNA levels were 10 5.5 and 10 6.5 copies/mL ( ). No significant difference was seen within P ϭ .15 groups of HBeAg-positive genotype B and C carriers (median: 10 9.1 and 10 7.6 copies/mL, respectively) and in genotype B and C HBeAg-negative subjects (median: 10 4.5 and 10 5.5 copies/mL, respectively; figure 1A) .
Results

Genotypes
The distribution of liver damage in the subjects with genotype B and C strains as measured by HAI scores is presented in figures 1B-1E and summarized in table 2. Persons with genotype C had higher inflammation scores than those with genotype B (
). Consistently, the mean ALT was 3.1 times P ϭ .009 the upper reference value (URV) in the genotype C group compared with in the genotype B group ( ). 1.2 ϫ URV P ϭ .0049 These findings reflect the higher virus load, and there was also a tendency for a more pronounced inflammation in relation to the virus load in persons with genotype C ( ; figure 1C) . P ϭ .050 Fibrosis scores were not statistically different; a fibrosis score of 3 or 4 was seen in 55% of carriers with genotype C versus 35% with genotype B (table 2) .
Mutations. The AGGrTGA mutation at nt 1762-1764 was the most common mutation in the core promoter region, appearing in 41.9% (18/43) of the subjects (figures 2, 3) . Persons with wild type (AGG) strains had significantly higher HBV DNA levels in the HBeAg positive group ( ; figure P ϭ .0076 2A). The TGA mutant was more common in persons with genotype C than with genotype B: 13 (68.4%) of 19 compared with 5 (21.7%) of 23, respectively ( ). In addition, 1 P ϭ .0059 genotype C strain showed an AGA mutant at nt 1762-1764. Presence of a TGA mutant was associated with more-severe inflammation and fibrosis ( and .0088, respectively). P ϭ .0036 This was seen in HBeAg-positive and -negative subjects ( figure  2D ). In fact, there was no association between the TGA mutation and HBeAg status: TGA mutants were found in 45% (10/22) of HBeAg-positive (in 1 as AGG/TGA mixture) and 33% (7/21) of HBeAg-negative subjects (in 2 as AGG/TGA mixtures). /T mixture, /T mixture, /T mixture, /G mixture. GenBank accession nos.:
Other mutations in the core promoter were more rare. Variation at nt 1751 was seen in 11 patients (6, G-1751; 5, T-1751) and was linked to genotype but not to liver damage. C-1752 was seen in 7 patients (6 with genotype C) and was associated with more-severe liver damage ( ) but always occurred P ϭ .0073 together with TGA at nt 1762-1764. A distinct genotype-related variation was observed at nt 1726-1730: All 23 genotype B strains had CTGAG, whereas 18 of 20 genotype C strains had AAGAC (2 had AGGAC). Less-consistent genotype-associated variation was seen at nt 1773 and 1799 ( figure 3) .
The GrA mutation at position 1896 that causes a TAG stop codon in the precore region was more frequent in genotype B (table 1; figure 4): Only 1 (5%) of 20 carriers with genotype C compared with 11 (48%) of 23 with genotype B were infected with precore TAG mutant strains only ( ). Presence P ϭ .0052 of a precore mutant strain was associated with HBeAg negativity ( ; for samples with isolated mutant P ϭ .004 P ! .0001 infection) and lower HBV DNA levels ( and .0001, P ϭ .001 respectively), and carriers with such strains tended to have lesssevere inflammation ( and .06, respectively) but not less P ϭ .17 fibrosis than associated with wild type infection (figure 4). In the HBeAg-negative phase, carriers with wild type infection had more-severe inflammation ( ), which was also related P ϭ .061 to virus load ( ). P ϭ .030 There was no overall association between precore and core promoter mutations, although there was a tendency for an inverse relation: A precore mutant was found in all HBeAg-negative samples with wild type AGG (at 1762-1764) infection, as shown in table 1 ( ). All of the HBeAg-negative subjects P ϭ .030 had a precore or a core promoter mutant or a combination of both. However, in 2 (patients 15 and 22) a "double wild type" strain was present in mixture with the mutant strain.
Five strains, all genotype C, had cytosine at position 1858 (C-1858). One of these, in a person with an HAI score of 4, had T-1857 and A-1897 (nucleotides that form a base pair in the pregenomic RNA stem loop), indicating a CrT/GrA double mutation at these sites, to create a TGA stop at codon 28.
Discussion
In the present study, the AGGrTGA mutation at nt 1762-1764 in the core promoter region was associated with more-severe inflammation and fibrosis in chronic hepatitis B. The finding agrees with previous reports [1, 2] and indicates that this mutation may be useful as a prognostic marker. The association was seen in both HBeAg-positive and -negative subjects and was independent of virus load. Overall, HBV DNA levels were similar in carriers with and without TGA mutants. However, persons who were HBeAg positive with TGA mutants, which have been attributed a higher rate of replication [5, 6, 8] , had a lower virus load ( ), showing that the P ϭ .007 host's immune response is probably more important for the HBV DNA level than inherent viral factors.
The TGA mutation has been associated with an "HBeAgnegative phenotype," and there has been some experimental support for this idea. However, in only one study was the reduction of precore RNA transcription (and thus HBeAg synthesis) relatively prominent [6] ; in the others it was absent [18] or moderate [5, 7, 8] . In the present series of patients, the TGA mutant was not associated with HBeAg negativity. In fact, the TGA mutation was more common in HBeAg-positive than in -negative persons, because of the high frequency of the mutation in HBeAg-positive genotype C subjects and wild type AGG in HBeAg-negative healthy carriers. These findings seem to contradict the suggestion in prior reports that effects on HBeAg expression are the major mechanism for the emergence of this mutant. Kidd-Ljunggren et al. [19] reported an overall association of the TGA mutation to HBeAg status, but this was not true for genotypes B and C: TGA mutants were found in 44% of HBeAg-positive subjects with these genotypes. Thus, other potential explanations for the frequent emergence of this mutation need to be investigated. For example, escape from proposed intracellular effects of cytokines on the core promoter [20] may be of importance, as may effects on the conformation of the 3 RNA stem loop [21] or the lysine-valine to methionineisoleucine exchange in the X protein.
Other mutations in the core promoter were rarer, and only the C-1752 mutation, which was always observed in conjunction with TGA at 1762-1764, was associated with liver damage, whereas variation at several other positions was genotype related. In particular, variation at nt 1726-1730 was strictly associated with genotype, and all genotype B strains had CTGAG. In agreement, we noted this variation in 9 genotype B GenBank sequences but not in any of 72 non-B genotype sequences (not shown). We also observed T at nt 1802 in all sequences of genotypes B, C, and F (the latter is restricted to the American continents) but not in the other genotypes. Thus, analysis of positions 1726-1730 and 1802 appears to be useful for identifying genotypes B and C.
An interesting finding was the association of genotype C with elevated inflammation scores. This agrees with the findings in a Japanese study of 1744 HBsAg carriers that found more liver damage in carriers with adr (invariably genotype C) compared with adw strains (which usually are genotype B in Japan) [12] . In that study, as in our present study, the more pronounced liver damage in adr carriers was related to a larger proportion being HBeAg-positive. Another Japanese study reported that adr carriers are more often HBeAg positive than are carriers infected with adw strains [22] . We have no explanation for this difference. However, as carriers with genotype B in the present study seemed more often to be in the early high-replicative (tolerance) or late low-active (surveillance) phase, genotype B could be associated with a faster transition through the immunoactive stage and a faster HBe seroconversion. This might to some extent be related to the fact that the precore GrA mutation at nt 1896 (which completely abrogates the synthesis and secretion of HBeAg) was more common in genotype B. Similarly, a cytosine at position 1858 (C-1858; seen in 5 patients) may delay HBeAg seroconversion in some persons with genotype C by preventing a precore TAG mutation. However, because HBe seroconversion in general implicates a reduction of HBV DNA levels of 199%, the finding seems to indicate that the viral replication in genotype B is more readily reduced by the immune response. This could be due to either genotype differences in antigen expression or regulation of viral replication, but this requires further study.
The low number of patients studied raises the possibility that the difference between genotypes is due to unrecognized selection bias or unknown factors, such as duration of infection. There was no difference in mean age among subjects with genotypes B and C. Although East Asia is a large region and possibly not homogeneous for HBV epidemiology, one might presume that a major proportion in both groups were infected in the perinatal period and thus that the difference in liver damage was not due to a difference in the duration of infection.
In summary, the present study shows that the AGGrTGA mutation at nt 1762-1764 is associated with more-severe liver damage in both HBeAg-positive and -negative subjects. Moreover, the results indicate that genotype C, compared with genotype B, is associated with a more pronounced liver inflammation, a lower frequency of precore mutants, and a higher frequency of 1762-1764 TGA mutants. The data point to the possibility of pathogenic differences among HBV genotypes and encourage further analysis of these associations in larger populations of HBV carriers.
